Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intelligent Patient Management Model on Medication Adherence of Pyrotinib
NCT06958627Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Medication adherence at 1-year. Started Apr 2024; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06958627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958627.